Document is current

Article History

Received: 8 April 2025

Accepted: 9 May 2025

First Online: 29 May 2025

Declarations

:

: Neenu Sebastian has received funding to support conference attendance from AbbVie. Omar Chircop and Tim H Clayton have no conflicts of interest. Firas C Kreeshan has been a speaker for AbbVie, Almirall, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; received honoraria and/or consultancy fee and/or travel bursaries and/or Educational grants have been from: Abbvie, Almirall, Galderma, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; and been an investigator (Sub-I) for Abbvie, Jansen and Eli Lilly. Hamish JA Hunter has received grant funding from AbbVie, Pfizer, Janssen and Merck Serono; honoraria and/or consultancy fees and/or travel bursaries from La Roche-Posay, Janssen, Abbvie, UCB, Sanofi Genzyme, Regeneron, Novartis, Almirall, Leo, Eli Lilly DICE Therapeutics, UNION Therapeutics, Pfizer and Galderma and has acted as an investigator for Janssen, Abbvie, UCB, Sanofi Genzyme, Novartis, Almirall, Leo, Eli Lilly, DICE Therapeutics, UNION Therapeutics, Evelo Biosciences Inc., ONO Pharmaceutical Co. Ltd. Bayer Pharmaceuticals, Artax Biopharma, Sudo Biosciences and No7 Beauty Company. Richard B Warren has acted as a consultant and/or speaker for and/or received research grants from AbbVie, Amgen, Almirall, Celgene, Eli Lilly, Pfizer, LEO Pharma, Novartis, Janssen Cilag, Medac, UCB Pharma and Xenoport. Richard B Warren is an Editor-in-Chief of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: The data is captured in routine clinical care assessing the safety and efficacy of patients using a new therapy in our centre. It's standard for us to audit new therapies in this way and additional ethics is not required.